登录新浪财经APP 搜索【信披】查看更多考评等级 截至2025年11月30日，公司通过上海证券交易所交易系统以集中竞价交易方式累计回购公司股份 958,020股，占公司总股本274,400,000股的比例为0.35%，回购成交的最高价为8.92元/股，最低价为7.02 元/股，支付的资金总额为人民币7,997,847.83元（不含印花税、交易佣金等交易费用）。 上述股份回购符合法律法规的规定及公司回购股份方案的要求。 重要内容提示： ■ 一、回购股份的基本情况 湖南南新制药股份有限公司（以下简称"公司"）于2025年4月28日召开第二届董事会第十五次会议，审 议通过了《关于以集中竞价交易方式回购公司股份方案的议案》，同意公司以不低于人民币1,000万元 （含）且不超过人民币2,000万元（含）的自有资金或自筹资金，通过集中竞价交易方式回购公司人民 币普通股（A股）股票，用于实施股权激励或员工持股计划，回购价格不超过人民币9.53元/股（含）， 回购期限为自公司董事会审议通过本次回购股份方案之日起12个月内。具体情况详见公司于2025年4月 30日在上海证券交易所网站（www.sse.com.cn）披露的《关于 ...

每经AI快讯，南新制药（SH 688189，收盘价：9.28元）12月1日晚间发布公告称，截至2025年11月30 日，公司通过上海证券交易所交易系统以集中竞价交易方式累计回购公司股份约96万股，占公司总股本 约2.74亿股的比例为0.35%，回购成交的最高价为8.92元/股，最低价为7.02元/股，支付的资金总额为人 民币约800万元。 2024年1至12月份，南新制药的营业收入构成为：医药制造占比99.99%，其他业务占比0.01%。 （记者 王晓波） 截至发稿，南新制药市值为25亿元。 每经头条（nbdtoutiao）——5年期大面积下线，3年期利率低至1.5%仍一单难求：要么"售罄"要么"额度 紧张"！中长期大额存单为何在消失？ ...

证券代码：688189 证券简称：南新制药 公告编号：2025-052 湖南南新制药股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/4/30 | | --- | --- | | 回购方案实施期限 | 2025/4/28~2026/4/27 | | 预计回购金额 | 1,000万元~2,000万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 958,020股 | | 累计已回购股数占总股本比例 | 0.35% | | 累计已回购金额 | 7,997,847.83元 | | 实际回购价格区间 | 7.02元/股~8.92元/股 | 特此公告。 湖南南新制药股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日召开第 二届董事会第十五次会议，审议通过了《关于以集中竞价交易方式回购公司股 ...

格隆汇12月1日丨南新制药（维权）(688189.SH)公布，截至2025年11月30日，公司通过上海证券交易所 交易系统以集中竞价交易方式累计回购公司股份958,020股，占公司总股本的比例为0.35%，回购成交的 最高价为8.92元/股，最低价为7.02元/股，支付的资金总额为人民币799.78万元（不含印花税、交易佣金 等交易费用）。 ...

Core Viewpoint - Nanjing Pharmaceutical has faced significant setbacks due to regulatory penalties and ongoing investigations, leading to continued financial losses and a volatile stock performance [1] Financial Performance - Nanjing Pharmaceutical has reported net losses for four consecutive years since 2021, with a loss of 0.69 billion yuan in the first three quarters of this year [1] - Despite a brief surge in stock price due to restructuring expectations, the stock has since halved from its peak earlier this year, although it remains up over 40% year-to-date [1] Regulatory Issues - The Ministry of Finance has imposed a fine of 100,000 yuan on Nanjing Pharmaceutical for inflating revenue by over 24 million yuan through fraudulent shipping documents and misreporting academic promotion expenses of 37 million yuan [1] - The company's head, Zhang Shixi, has also been fined 50,000 yuan for his responsibility in these violations [1] - Additionally, the China Securities Regulatory Commission has initiated an investigation into the company's annual report disclosure violations [1]

Core Viewpoint - The A-share market experienced a significant rally on November 25, with the ChiNext Index rising nearly 2%, driven by a surge in flu-related stocks due to an increase in flu activity across the country [1] Group 1: Market Performance - The ChiNext Index saw a nearly 2% increase on November 25, indicating strong market performance [1] - Flu-related stocks, such as Jindike and Xinhua Pharmaceutical, reached their daily limit up, reflecting heightened investor interest [1] Group 2: Flu Activity and Sales Data - National flu activity has rapidly increased in November, with Beijing entering a high incidence period for respiratory infectious diseases [1] - Sales of Oseltamivir surged by 237% over the past week, while sales of Maviral (Sofosbuvir) increased by 180% [1] - Data from Meituan indicates that special flu medications in Beijing have seen a month-on-month growth exceeding 130%, with Maviral growing over 110% and Oseltamivir granules increasing by over 85% [1] Group 3: Investment Opportunities - According to Everbright Securities, the rising flu epidemic is likely to increase public and market attention, leading to a growth in demand for flu prevention and treatment products [1] - Investment opportunities are suggested in flu vaccines, virus testing, cold medications, and special antiviral drugs, as well as blood products as a response to complex epidemic situations [1]

Group 1 - The demand for flu-related medications is rising significantly as the flu season approaches, with several stocks in the sector experiencing price surges [1] - Notable stocks that have reached their daily limit include Jindike, Peking University Medicine, and Te Yi Pharmaceutical, among others [1] - Data from Alibaba Health indicates a more than 500% week-on-week increase in the number of people purchasing antiviral flu medications, with Mabalosavir showing a remarkable over 600% increase [1] Group 2 - Experts warn that the H3N2 strain circulating this year is different from previous years, leading to lower immunity in the population and increased transmission risk [2] - The flu virus is known to undergo antigenic drift, but current strains are still within seasonal levels and do not indicate a stronger evolution of the virus [2] Group 3 - Companies are actively ensuring the supply of flu medications and vaccines in response to rising demand [3] - Dongyang Sunshine, a major supplier of Oseltamivir, reports comprehensive coverage of its products across hospitals, pharmacies, and online platforms, maintaining sufficient inventory [3] - Hualan Biological has noted a significant increase in demand for flu vaccines since October, with plans to enhance market supply and ensure timely delivery through cold chain logistics [3]

Core Insights - The flu season has arrived earlier than expected, leading to increased activity in flu-related stocks in the A-share market [1] - Significant sales increases have been reported for antiviral medications, with Oseltamivir sales up 237% and Mabalaosavir up 180% in the past week [1] Stock Performance - Notable stock movements include: - Yipinhong (一品红) up 13% - Hendi Pharmaceutical (亨迪药业) up nearly 11% - Special One Pharmaceutical (特一药业) and Guangji Pharmaceutical (广济药业) both hitting the 10% daily limit up - Other companies like Hainan Haiyao (海南海药) and Peking University Pharmaceutical (北大医药) also saw significant gains [1][2] - The overall market sentiment is positive, with many flu-related stocks experiencing substantial year-to-date increases, such as: - Yipinhong with a year-to-date increase of 225.09% - Hainan Haiyao with a 75.37% increase [2] Consumer Behavior - Data from Alibaba Health indicates a marked increase in the attention and purchase volume of flu medications over the past two weeks, with a more than 500% week-on-week growth in the number of buyers for antiviral drugs [1] - Mabalaosavir has shown exceptional performance, with a 600% increase in the number of buyers compared to the previous period, reflecting heightened consumer awareness regarding flu prevention and treatment [1]

Core Viewpoint - The company, Nanxin Pharmaceutical, is leveraging its technological advantages in the field of cold and antiviral drugs to ensure the production and supply of related treatment medications amid rising influenza virus activity levels in China [1][2]. Group 1: Product Portfolio and Innovation - Nanxin Pharmaceutical has established a comprehensive product matrix for influenza prevention and treatment, covering injectable and oral forms, as well as therapies for viral and bacterial infections, and antipyretic analgesics [1]. - The company's Palivizumab Sodium Injection is a representative of neuraminidase inhibitors, recognized as a core choice for influenza treatment in the latest national guidelines [1]. - The company is currently in the III phase of clinical trials for an inhalation solution of Palivizumab, which utilizes nebulization for direct action on the respiratory tract, enhancing patient compliance and offering a new option for influenza treatment [2]. Group 2: Targeted Treatments for Specific Populations - The company has developed a formulation of Oseltamivir Phosphate suitable for young children and elderly patients, addressing the need for appropriate dosage forms in these demographics [1]. - Nanxin Pharmaceutical offers a range of supportive treatments for influenza symptoms, including exclusive products like Compound Ibuprofen Tablets and formulations specifically designed for children, which have become common choices in pediatric care [2]. Group 3: Future Outlook and Commitment - The company aims to continuously optimize its product structure and provide efficient solutions for the prevention and treatment of influenza and other respiratory diseases, demonstrating its commitment to public health [2].

Core Viewpoint - The Ministry of Finance of China has issued administrative penalties against Hunan Nanxin Pharmaceutical Co., Ltd. for accounting irregularities, including the overstatement of revenue and costs, as well as fraudulent academic promotion expenses [1][2][3]. Group 1: Accounting Irregularities - Nanxin Pharmaceutical's subsidiary, Guangzhou Nanxin Pharmaceutical Co., Ltd., recognized 2023 revenue of 28,296,301.07 yuan and cost of goods sold of 4,412,163.38 yuan based on falsified shipping documents [2][6]. - The company overstated 2023 revenue by 24,539,733.46 yuan and costs by 3,839,043.33 yuan due to discrepancies in shipping and customer acceptance processes [2][14]. - The company was found to have used identical promotional activity photos across different regions and had discrepancies in signatures of attendees, indicating fraudulent reporting of academic promotion expenses totaling 37,000,000.00 yuan [3][11]. Group 2: Penalties Imposed - The Ministry of Finance imposed a fine of 100,000 yuan on Nanxin Pharmaceutical for the accounting violations [3][8]. - Zhang Shixi, the company’s responsible unit head, was fined 50,000 yuan for his role in the violations [3][12]. - Li Liang, the head of accounting, received a fine of 30,000 yuan for his responsibility in the accounting issues [3][15]. Group 3: Company Background - Nanxin Pharmaceutical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on March 26, 2020, with an initial offering price of 34.94 yuan per share and raised a total of 1.223 billion yuan [4][6]. - The company has undergone multiple capital increases, including a stock dividend distribution that increased its total share capital from 140 million to 196 million shares in 2022, and further to 274.4 million shares in 2023 [5][6].